Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

INhibiting mechanoTRansduction as a novel approach for Oncology theraPY (INTROPY)

Descrizione del progetto

Prendere di mira la rigidità del tumore

I tessuti presentano per natura una rigidità che consente loro di percepire le forze meccaniche e di rispondere e resistere alla loro deformazione, una rigidità che dipende dalla composizione del tessuto e dalla matrice extracellulare. In molti tumori solidi, l’aumento della rigidità incentiva la progressione del cancro. Il progetto INTROPY, finanziato dal CER, si concentra su una proteina che si dispiega in modo specifico nei tessuti rigidi, rappresentando un nuovo bersaglio per la terapia. Il progetto mira a inibire questa proteina per bloccare la progressione del cancro guidata dalla rigidità testando i composti promettenti in modelli cellulari, ottimizzandone le proprietà con la chimica medicinale e fornendo una prova di concetto del loro potenziale in qualità di agenti terapeutici di prima classe.

Obiettivo

Increased tissue stiffness is a hallmark of many solid tumours, driving tumour progression. This occurs through mechanotransduction, the process by which cells sense and respond to mechanical signals. Our lab has identified a key interaction between two proteins, essential for mechanotransduction. This interaction is triggered by force-induced unfolding of a target protein, which occurs only in stiff tissues. Hence, we propose a novel therapeutic approach that targets mechanotransduction by inhibiting the stiffness-induced unfolding of the target protein. This innovative approach has the potential to transform cancer therapy and provide new insights into the role of mechanical signals in disease progression. We developed a thermal shift assay to identify molecules that stabilize the target and inhibit its unfolding. High throughput Screening (HTS) of ~5,000 molecules resulted in 4 hits with confirmed specific binding by NMR analysis. Two additional hits were identified each through structure-based virtual screening and a peptide-based approach, with confirmed binding through NMR analysis. In this project, we aim to validate these 6 hits, and to provide proof-of-concept evidence of their potential for cancer therapy. First, we will validate hits in vitro and in cellular assays. Second, we will optimize them with medicinal chemists to obtain lead molecules. Third, we will evaluate resulting lead molecules in an in vivo mouse breast cancer model. By the end of the project, we expect our data to be sufficient to attract private investment and establish a spin-off company to pursue drug development into clinical phases. This will lead to a first-inclass mechanoinhibitor drug, with potential applications in cancer (with a focus on breast and pancreatic cancer) and other conditions characterized by mechanical stress, such as fibrosis.

Campo scientifico (EuroSciVoc)

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) ERC-2024-POC

Vedi tutti i progetti finanziati nell’ambito del bando

Istituzione ospitante

FUNDACIO INSTITUT DE BIOENGINYERIA DE CATALUNYA
Contributo netto dell'UE
€ 150 000,00
Indirizzo
CARRER BALDIRI REIXAC PLANTA 2A 10-12
08028 Barcelona
Spagna
Regione
Este Cataluña Barcelona
Tipo di attività
Research Organisations
Collegamenti
Costo totale
Nessun dato

Beneficiari (1)